Telmisartan Teva

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
25-03-2021
Toote omadused Toote omadused (SPC)
25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
26-06-2015

Toimeaine:

Telmisartan

Saadav alates:

Teva B.V.

ATC kood:

C09CA07

INN (Rahvusvaheline Nimetus):

telmisartan

Terapeutiline rühm:

Agents acting on the renin-angiotensin system

Terapeutiline ala:

Hypertension

Näidustused:

Treatment of essential hypertension in adults

Toote kokkuvõte:

Revision: 11

Volitamisolek:

Withdrawn

Loa andmise kuupäev:

2010-01-25

Infovoldik

                                43
B. PACKAGE LEAFLET
44
PACKAGE LEAFLET: INFORMATION FOR THE USER
TELMISARTAN TEVA 20 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Telmisartan Teva is and what it is used for
2.
What you need to know before you take Telmisartan Teva
3.
How to take Telmisartan Teva
4.
Possible side effects
5.
How to store Telmisartan Teva
6.
Contents of the pack and other information
1.
WHAT TELMISARTAN TEVA IS AND WHAT IT IS USED FOR
Telmisartan Teva belongs to a class of medicines known as
angiotensin-II receptor antagonists.
Angiotensin II is a substance occurring in the body, which causes your
blood vessels to narrow, thus
increasing your blood pressure. Telmisartan Teva blocks this effect of
angiotensin II so that the blood vessels
relax, and your blood pressure is lowered.
Telmisartan Teva is used to treat essential hypertension (high blood
pressure) in adults. ‘Essential’ means
that the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead sometimes
to heart attacks, heart or kidney failure, strokes or blindness. There
are usually no symptoms of high blood
pressure before damage occurs. Thus it is important to regularly
measure blood pressure to verify if it is
within the normal range.
Telmisartan Teva is also used to reduce cardiovascular events (i.e.
heart attack or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, 
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Telmisartan Teva 20 mg tablets
Telmisartan Teva 40 mg tablets
Telmisartan Teva 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Telmisartan Teva 20 mg tablets
Each tablet contains 20 mg telmisartan
Telmisartan Teva 40 mg tablets
Each tablet contains 40 mg telmisartan
Telmisartan Teva 80 mg tablets
Each tablet contains 80 mg telmisartan
Excipients with known effect:
Telmisartan Teva 20 mg tablets
Each tablet contains 21.4 mg sorbitol (E420)
Telmisartan Teva 40 mg tablets
Each tablet contains 42.8 mg sorbitol (E420)
Telmisartan Teva 80 mg tablets
Each tablet contains 85.6 mg sorbitol (E420)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Telmisartan Teva 20 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7458".
Telmisartan Teva 40 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7459".
Telmisartan Teva 80 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7460".
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
3
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:
•
manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or peripheral
arterial disease) or
•
type 2 diabetes mellitus with documented target organ damage
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Treatment of essential hypertension _
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of 20 mg.
In cases where the target blood pressure is not achieved, the dose of
telmisartan can be increased to a
maximum
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 25-03-2021
Toote omadused Toote omadused bulgaaria 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 26-06-2015
Infovoldik Infovoldik hispaania 25-03-2021
Toote omadused Toote omadused hispaania 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 26-06-2015
Infovoldik Infovoldik tšehhi 25-03-2021
Toote omadused Toote omadused tšehhi 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 26-06-2015
Infovoldik Infovoldik taani 25-03-2021
Toote omadused Toote omadused taani 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande taani 26-06-2015
Infovoldik Infovoldik saksa 25-03-2021
Toote omadused Toote omadused saksa 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande saksa 26-06-2015
Infovoldik Infovoldik eesti 25-03-2021
Toote omadused Toote omadused eesti 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande eesti 26-06-2015
Infovoldik Infovoldik kreeka 25-03-2021
Toote omadused Toote omadused kreeka 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 26-06-2015
Infovoldik Infovoldik prantsuse 25-03-2021
Toote omadused Toote omadused prantsuse 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 26-06-2015
Infovoldik Infovoldik itaalia 25-03-2021
Toote omadused Toote omadused itaalia 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 26-06-2015
Infovoldik Infovoldik läti 25-03-2021
Toote omadused Toote omadused läti 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande läti 26-06-2015
Infovoldik Infovoldik leedu 25-03-2021
Toote omadused Toote omadused leedu 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande leedu 26-06-2015
Infovoldik Infovoldik ungari 25-03-2021
Toote omadused Toote omadused ungari 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande ungari 26-06-2015
Infovoldik Infovoldik malta 25-03-2021
Toote omadused Toote omadused malta 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande malta 26-06-2015
Infovoldik Infovoldik hollandi 25-03-2021
Toote omadused Toote omadused hollandi 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 26-06-2015
Infovoldik Infovoldik poola 25-03-2021
Toote omadused Toote omadused poola 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande poola 26-06-2015
Infovoldik Infovoldik portugali 25-03-2021
Toote omadused Toote omadused portugali 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande portugali 26-06-2015
Infovoldik Infovoldik rumeenia 25-03-2021
Toote omadused Toote omadused rumeenia 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 26-06-2015
Infovoldik Infovoldik slovaki 25-03-2021
Toote omadused Toote omadused slovaki 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 26-06-2015
Infovoldik Infovoldik sloveeni 25-03-2021
Toote omadused Toote omadused sloveeni 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 26-06-2015
Infovoldik Infovoldik soome 25-03-2021
Toote omadused Toote omadused soome 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande soome 26-06-2015
Infovoldik Infovoldik rootsi 25-03-2021
Toote omadused Toote omadused rootsi 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 26-06-2015
Infovoldik Infovoldik norra 25-03-2021
Toote omadused Toote omadused norra 25-03-2021
Infovoldik Infovoldik islandi 25-03-2021
Toote omadused Toote omadused islandi 25-03-2021
Infovoldik Infovoldik horvaadi 25-03-2021
Toote omadused Toote omadused horvaadi 25-03-2021
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 26-06-2015

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu